Therapeutic Drug Monitoring Market Analysis By Product (Consumables, Equipment, Data Management Services), By Technology (Immunoassays, Proteomic Technologies) By Drug Class (Anti-epileptic s, Antibiotics, Immunosuppressants, Anti-arrhythmics) By End-use (Hospital Labs, Private Labs), and Segment Forecasts To 2024

Published: Aug, 2016 | Pages: 80 | Publisher: Grand View Research
Industry: Biotechnology | Report Format: Electronic (PDF)

The global therapeutic drug monitoring market is expected to reach over USD 3.37 billion by 2024, according to a new report by Grand View Research, Inc. Recent technological advancements in the Point-of-Care (PoC) devices hold considerable transformative promises for the personalized predictive and preventive medicine. Therapeutic Drug Monitoring (TDM) forms a foundational part to the devising of personalized treatment plans for patients; and the advent of PoC diagnostic devices that yield quantitative measurements of the drug concentration plays a pivotal role in supporting the development of the precision medicine field in the healthcare sector. However, the broad application of the PoC devices for patient monitoring is still lagging behind. The presence of this untapped opportunity is one of the high impact rendering drivers for the market growth.

The employment of continuous therapeutic drug and metabolite monitoring in the early phase of the medication regimen, administered post-organ transplantation, forms a major application in the areas of critical care medicine and organ transplantation, which is expected to propel the growth of the therapeutic drug monitoring market over the forecast period. In addition, the imposing burden of diseases, such as epilepsy and cancer, the rising government initiatives, and the presence of high-unmet needs are some of the crucial determinants expected to further favor the emergence of this market.

Further key findings from the study suggest:

The consumables segment covered over 65% of the market share in 2015 as a consequence of the extensive requirement of the consumables in the research laboratories and due to the repeat purchase of the kits and reagents.

The immunoassay segment held the largest market share in 2015. The presence of several commercially available immunoassays combined with their associated benefits including the cost effectiveness and easy-to-handle nature of the products are the key drivers for the growth of this segment.

The proteomics category is expected to be the fastest growing technology segment due to the advent of various proteomic technologies, such as isotope-coded affinity tags, next generation sequencing, and protein microarray platforms that enable rapid mining of the proteome.

The hospital is the largest end-use segment with a share of over 60% in 2015. In larger hospitals, various underlying technologies are employed to perform immunoassays; these comprise chemiluminescence, nephelometry, colorimetry, and fluorescence, which are available for the testing of a wide ranging drug panel.

The drug monitoring for the immunosuppressants is one of the fastest growing application segments owing to the introduction of novel TDM point-of-care testing devices for the evaluation of the concentration of administered immunosuppressants and the complementary metabolites, in order to achieve a prominent therapeutic effect while preventing drug toxicity events in patients that have undergone transplantations.

In 2015, North America was the highest revenue generating region with revenue generated over USD 900 million. The rising number of R&D activities coupled with the high awareness about personalized therapy is the major determining factor for the large share captured by the North America region.

Few of the leading market players are Roche Diagnostics, Siemens Healthcare GmbH, Thermo Fisher Scientific, Inc., Bio-Rad Laboratories, Inc., Beckman Coulter, Inc., Abbott Laboratories, Inc., Agilent Technologies, Inc., bioMerieux, Inc., and Alere, Inc. The persistent R&D efforts are being undertaken along with numerous other strategic endeavors being adopted by the market players with the objective of enhancing the present drug monitoring practices and to develop novel technologies.

Table of Contents

Chapter 1.Methodology And Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
1.3. List of Data Sources
Chapter 2. Executive Summary
2.1. Therapeutic drug monitoring market - Industry Snapshot and Key Buying Criteria, 2013 - 2024
Chapter 3. Therapeutic Drug Monitoring Market, Industry Outlook
3.1. Market segmentation
3.2. Market size and growth prospects
3.3. Therapeutic drug monitoring market: Market dynamics
3.3.1. Market driver analysis
3.3.2. Market restraint analysis
3.4. Key opportunities prioritized
3.5. Industry Analysis - Porter's
3.6. Therapeutic drug monitoring market PESTEL analysis, 2015
Chapter 4. Therapeutic Drug Monitoring Market, Product Outlook
4.1. Therapeutic drug monitoring market share by product, 2015 & 2024
4.2. Consumables
4.2.1. Consumables market estimates and forecasts, 2013 - 2024 (USD Million)
4.3. Equipment
4.3.1. Equipment market estimates and forecasts, 2013 - 2024 (USD Million)
4.4. Others
4.4.1. Others market estimates and forecasts, 2013 - 2024 (USD Million)
Chapter 5. Therapeutic Drug Monitoring Market, Technology Outlook
5.1. Therapeutic drug monitoring market share by technology, 2015 & 2024
5.2. Immunoassays
5.2.1. Immunoassays market estimates and forecasts, 2013 - 2024 (USD Million)
5.3. Proteomic technologies
5.3.1. Proteomic technologies market estimates and forecasts, 2013 - 2024 (USD Million)
5.4. Others
5.4.1. Others market estimates and forecasts, 2013 - 2024 (USD Million)
Chapter 6. Therapeutic Drug Monitoring Market, Drug Class Outlook
6.1. Therapeutic drug monitoring market share by drug class, 2015 & 2024
6.2. Anti - epileptics
6.2.1. Anti - epileptic market estimates and forecasts, 2013 - 2024 (USD Million)
6.3. Antibiotics
6.3.1. Antibiotics market estimates and forecasts, 2013 - 2024 (USD Million)
6.4. Immunosuppressants
6.4.1. Immunosuppressants market estimates and forecasts, 2013 - 2024 (USD Million)
6.5. Psychoactive drugs
6.5.1. Psychoactive drugs market estimates and forecasts, 2013 - 2024 (USD Million)
6.6. Anti-arrhythmic drugs
6.6.1. Anti-arrhythmic drugs market estimates and forecasts, 2013 - 2024 (USD Million)
6.7. Others
6.7.1. Others drug market estimates and forecasts, 2013 - 2024 (USD Million)
Chapter 7. Therapeutic Drug Monitoring Market, End - use Outlook
7.1. Therapeutic drug monitoring market share by end - use, 2015 & 2024
7.2. Hospital labs
7.2.1. Hospital labs market estimates and forecasts, 2013 - 2024 (USD Million)
7.3. Private labs
7.3.1. Private labs market estimates and forecasts, 2013 - 2024 (USD Million)
7.4. Others
7.4.1. Others market estimates and forecasts, 2013 - 2024 (USD Million)
Chapter 8. Drug Monitoring Market Regional Outlook
8.1. Therapeutic drug monitoring market share by region, 2015 & 2024
8.2. North America
8.2.1. North America market estimates and forecasts, by product, 2013 - 2024 (USD Million)
8.2.1.1. U.S. market estimates and forecasts
8.2.1.2. Canada market estimates and forecasts
8.2.2. North America market estimates and forecasts, by technology type, 2013 - 2024 (USD Million)
8.2.2.1. U.S. market estimates and forecasts
8.2.2.2. Canada market estimates and forecasts
8.2.3. North America market estimates and forecasts, by drug class, 2013 - 2024 (USD Million)
8.2.3.1. U.S. market estimates and forecasts
8.2.3.2. Canada market estimates and forecasts
8.2.4. North America market estimates and forecasts, by end - use type, 2013 - 2024 (USD Million)
8.2.4.1. U.S. market estimates and forecasts
8.2.4.2. Canada market estimates and forecasts
8.3. Europe
8.3.1. Europe market estimates and forecasts, by product , 2013 - 2024 (USD Million)
8.3.1.1. UK market estimates and forecasts
8.3.1.2. Germany market estimates and forecasts
8.3.2. Europe market estimates and forecasts, by technology, 2013 - 2024 (USD Million)
8.3.2.1. UK market estimates and forecasts
8.3.2.2. Germany market estimates and forecasts
8.3.3. Europe market estimates and forecasts, by drug class, 2013 - 2024 (USD Million)
8.3.3.1. UK market estimates and forecasts
8.3.3.2. Germany market estimates and forecasts
8.3.4. Europe market estimates and forecasts, by end - use, 2013 - 2024 (USD Million)
8.3.4.1. UK market estimates and forecasts
8.3.4.2. Germany market estimates and forecasts
8.4. Asia Pacific
8.4.1. Asia Pacific market estimates and forecasts, by product, 2013 - 2024 (USD Million)
8.4.1.1. Japan market estimates and forecasts
8.4.1.2. China market estimates and forecasts
8.4.2. Asia Pacific market estimates and forecasts, by technology, 2013 - 2024 (USD Million)
8.4.2.1. Japan market estimates and forecasts
8.4.2.2. China market estimates and forecasts
8.4.3. Asia Pacific market estimates and forecasts, by drug class, 2013 - 2024 (USD Million)
8.4.3.1. Japan market estimates and forecasts
8.4.3.2. China market estimates and forecasts
8.4.4. Asia Pacific market estimates and forecasts, by end - use , 2013 - 2024 (USD Million)
8.4.4.1. Japan market estimates and forecasts
8.4.4.2. China market estimates and forecasts
8.5. Latin America
8.5.1. Latin America market estimates and forecasts, by product, 2013 - 2024 (USD Million)
8.5.1.1. Brazil market estimates and forecasts
8.5.2. Latin America market estimates and forecasts, by technology, 2013 - 2024 (USD Million)
8.5.2.1. Brazil market estimates and forecasts
8.5.3. Latin America market estimates and forecasts, by drug class, 2013 - 2024 (USD Million)
8.5.3.1. Brazil market estimates and forecasts
8.5.4. Latin America market estimates and forecasts, by end - use, 2013 - 2024 (USD Million)
8.5.4.1. Brazil market estimates and forecasts
8.6. MEA
8.6.1. MEA market estimates and forecasts, by product , 2013 - 2024 (USD Million)
8.6.1.1. South Africa market estimates and forecast
8.6.2. MEA market estimates and forecasts, by technology, 2013 - 2024 (USD Million)
8.6.2.1. South Africa market estimates and forecast
8.6.3. MEA market estimates and forecasts, by drug class, 2013 - 2024 (USD Million)
8.6.3.1. South Africa market estimates and forecast
8.6.4. MEA market estimates and forecasts, by end - use, 2013 - 2024 (USD Million)
8.6.4.1. South Africa market estimates and forecast
Chapter 9. Competitive Landscape
9.1. Roche Diagnostics
9.1.1. Company Overview
9.1.2. Financial Performance
9.1.3. Product Benchmarking
9.1.4. Strategic Initiatives
9.2. biomérieux, Inc.
9.2.1. Company Overview
9.2.2. Financial Performance
9.2.3. Product Benchmarking
9.2.4. Strategic Initiatives
9.3. Abbott Laboratories, Inc.
9.3.1. Company Overview
9.3.2. Financial Performance
9.3.3. Product Benchmarking
9.3.4. Strategic Initiatives
9.4. Danaher Corporation
9.4.1. Company Overview
9.4.2. Financial Performance
9.4.3. Product Benchmarking
9.4.4. Strategic Initiatives
9.5. Alere, Inc.
9.5.1. Company Overview
9.5.2. Financial Performance
9.5.3. Product Benchmarking
9.5.4. Strategic Initiatives
9.6. Agilent Technologies, Inc.
9.6.1. Company Overview
9.6.2. Financial Performance
9.6.3. Product Benchmarking
9.6.4. Strategic Initiatives
9.7. Thermo Fisher Scientific, Inc.
9.7.1. Company Overview
9.7.2. Financial Performance
9.7.3. Product Benchmarking
9.7.4. Strategic Initiatives
9.8. Siemens Healthcare GmbH
9.8.1. Company Overview
9.8.2. Financial Performance
9.8.3. Product Benchmarking
9.8.4. Strategic Initiatives
9.9. Bio-Rad Laboratories, Inc.
9.9.1. Company Overview
9.9.2. Financial Performance
9.9.3. Product Benchmarking
9.9.4. Strategic Initiatives

List of Tables


TABLE 1 Therapeutic drug monitoring market - Industry Summary & Critical Success Factors (CSFs)
TABLE 2 Therapeutic drug monitoring market, by product, 2013 - 2024 (USD million)
TABLE 3 Therapeutic drug monitoring market,by technology, 2013 - 2024 (USD million)
TABLE 4 Therapeutic drug monitoring market, by drug class, 2013 - 2024 (USD million)
TABLE 5 Therapeutic drug monitoring, by end - use, 2013 - 2024 (USD million)
TABLE 6 Therapeutic drug monitoring, by region, 2013 - 2024 (USD million)
TABLE 7 Therapeutic drug monitoring market - Key market driver analysis
TABLE 8 Therapeutic drug monitoring market - Key market restraint analysis
TABLE 9 North America therapeutic drug monitoring market, by product, 2013 - 2024 (USD million)
TABLE 10 North America therapeutic drug monitoring market, by technology, 2013 - 2024 (USD million)
TABLE 11 North America therapeutic drug monitoring, by drug class, 2013 - 2024 (USD million)
TABLE 12 North America therapeutic drug monitoring, by end - use, 2013 - 2024 (USD million)
TABLE 13 U.S. therapeutic drug monitoring market, by product, 2013 - 2024 (USD million)
TABLE 14 U.S. therapeutic drug monitoring market, by technology, 2013 - 2024 (USD million)
TABLE 15 U.S. therapeutic drug monitoring, by drug class, 2013 - 2024 (USD million)
TABLE 16 U.S. therapeutic drug monitoring market, by end - use, 2013 - 2024 (USD million)
TABLE 17 Canada therapeutic drug monitoring market, by product, 2013 - 2024 (USD million)
TABLE 18 Canada therapeutic drug monitoring market, by technology, 2013 - 2024 (USD million)
TABLE 19 Canada therapeutic drug monitoring market, by drug class, 2013 - 2024 (USD million)
TABLE 20 Canada therapeutic drug monitoring market, by end - use, 2013 - 2024 (USD million)
TABLE 21 Europe therapeutic drug monitoring market, by product, 2013 - 2024 (USD million)
TABLE 22 Europe therapeutic drug monitoring market, by technology, 2013 - 2024 (USD million)
TABLE 23 Europe therapeutic drug monitoring market, by drug class, 2013 - 2024 (USD million)
TABLE 24 Europe therapeutic drug monitoring market, by end - use, 2013 - 2024 (USD million)
TABLE 25 UK therapeutic drug monitoring market, by product, 2013 - 2024 (USD million)
TABLE 26 UK therapeutic drug monitoring market, by technology, 2013 - 2024 (USD million)
TABLE 27 UK therapeutic drug monitoring market, by drug class, 2013 - 2024 (USD million)
TABLE 28 UK therapeutic drug monitoring market, by end - use, 2013 - 2024 (USD million)
TABLE 29 Germany therapeutic drug monitoring market, by product, 2013 - 2024 (USD million)
TABLE 30 Germany therapeutic drug monitoring market, by technology, 2013 - 2024 (USD million)
TABLE 31 Germany therapeutic drug monitoring market, by drug class, 2013 - 2024 (USD million)
TABLE 32 Germany therapeutic drug monitoring market, by end - use, 2013 - 2024 (USD million)
TABLE 33 Aisa Pacific therapeutic drug monitoring market, by product, 2013 - 2024 (USD million)
TABLE 34 Aisa Pacific therapeutic drug monitoring market market, by technology, 2013 - 2024 (USD million)
TABLE 35 Aisa Pacific therapeutic drug monitoring market market, by drug class, 2013 - 2024 (USD million)
TABLE 36 Aisa Pacific therapeutic drug monitoring market market, by end - use, 2013 - 2024 (USD million)
TABLE 37 Japan therapeutic drug monitoring market market, by product, 2013 - 2024 (USD million)
TABLE 38 Japan therapeutic drug monitoring market market, by technology, 2013 - 2024 (USD million)
TABLE 39 Japan therapeutic drug monitoring market market, by drug class, 2013 - 2024 (USD million)
TABLE 40 Japan therapeutic drug monitoring market market, by end - use, 2013 - 2024 (USD million)
TABLE 41 China therapeutic drug monitoring market, by product, 2013 - 2024 (USD million)
TABLE 42 China therapeutic drug monitoring market market, by technology, 2013 - 2024 (USD million)
TABLE 43 China therapeutic drug monitoring market, by drug class, 2013 - 2024 (USD million)
TABLE 44 China therapeutic drug monitoring market, by end - use, 2013 - 2024 (USD million)
TABLE 45 Latin America therapeutic drug monitoring market, by product, 2013 - 2024 (USD million)
TABLE 46 Latin America therapeutic drug monitoring market, by technology, 2013 - 2024 (USD million)
TABLE 47 Latin America therapeutic drug monitoring market, by drug class, 2013 - 2024 (USD million)
TABLE 48 Latin America therapeutic drug monitoring market, by end - use, 2013 - 2024 (USD million)
TABLE 49 Brazil therapeutic drug monitoring market, by product, 2013 - 2024 (USD million)
TABLE 50 Brazil therapeutic drug monitoring market, by technology, 2013 - 2024 (USD million)
TABLE 51 Brazil therapeutic drug monitoring market, by drug class, 2013 - 2024 (USD million)
TABLE 52 Brazil therapeutic drug monitoring market, by end - use, 2013 - 2024 (USD million
TABLE 53 MEA therapeutic drug monitoring market, by product, 2013 - 2024 (USD million)
TABLE 54 MEA therapeutic drug monitoring market, by technology, 2013 - 2024 (USD million)
TABLE 55 MEA therapeutic drug monitoring market, by drug class, 2013 - 2024 (USD million)
TABLE 56 MEA therapeutic drug monitoring market, by end - use, 2013 - 2024 (USD million)
TABLE 57 South Africa therapeutic drug monitoring market, by product, 2013 - 2024 (USD million)
TABLE 58 South Africa therapeutic drug monitoring market, by technology, 2013 - 2024 (USD million)
TABLE 59 South Africa therapeutic drug monitoring market, by drug class, 2013 - 2024 (USD million)
TABLE 60 South Africa therapeutic drug monitoring market, by end - use, 2013 - 2024 (USD million)